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We have synthesized and characterized MP-III-022 ((R)8-ethynyl-6-(2-ﬂuorophenyl)-N,4-dimethyl-
4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide) in vitro and in vivo as a binding- and efﬁcacy-
selective positive allosteric modulator of GABAA receptors containing the α5 subunit (α5GABAARs). By
approximation of the electrophysiological responses which the estimated free rat brain concentrations
can induce, we demonstrated that convenient systemic administration of MP-III-022 in the dose range 1–
10 mg/kg may result in a selective potentiation, over a wide range from mild to moderate to strong, of
α5βγ2 GABAA receptors. For eliciting a comparable range of potentiation, the widely studied parent
ligand SH-053-2′F-R-CH3 containing an ester moiety needs to be administered over a much wider dose
range (10–200 mg/kg), but at the price of activating non-α5 GABAARs as well as the desired α5GABAARs
at the highest dose. At the dose of 10 mg/kg, which elicits a strong positive modulation of α5GABAARs,
MP-III-022 caused mild, but signiﬁcant muscle relaxation, while at doses 1–10 mg/kg was devoid of
ataxia, sedation or an inﬂuence on the anxiety level, characteristic for non-selective benzodiazepines. As
an amide compound with improved stability and kinetic properties, MP-III-022 may represent an opti-
mized tool to study the inﬂuence of α5GABAARs on the neuronal pathways related to CNS disorders such
as schizophrenia, Alzheimer's disease, Down syndrome or autism.
& 2016 Elsevier B.V. All rights reserved.1. Introduction
Gamma-aminobutyric acid (GABA)A-receptors mediate the
majority of inhibitory neurotransmission in adult brain and re-
present a prominent therapeutic target. Most notably, benzodia-
zepines are GABAergic drugs widely used in treatment of anxiety,
insomnia, epilepsy and muscular spasms, and elucidation of their
mechanism of action has helped the understanding of the role of
various GABAA receptor populations in normal and pathological
conditions. Speciﬁcally, the vast majority of pentameric GABAA
receptors contain an α1, α2, α3 or α5 subunit together with a
neighboring γ2 subunit, and benzodiazepines such as diazepam
act as positive allosteric modulators at all these receptors (Rudolph
and Möhler, 2014).
Among the diazepam-sensitive target populations, α5GABAARs. Savić).are the least abundant (o5% of total) and with the most restricted
distribution (Rudolph and Möhler, 2014), both of which are ex-
cellent characteristics for development of subtype selective li-
gands. Most of the patents in the ﬁeld of benzodiazepines claim
the therapeutic usefulness of both, positive and negative selective
modulators of α5GABAARs (Guerrini and Ciciani, 2012). As studies
in α5GABAAR knock-out mice revealed pro-cognitive effects (Col-
linson et al., 2002; Crestani et al., 2002), development of negative
allosteric modulators selective for these receptors has been in-
itiated ﬁrstly (Maubach, 2003), and resulted in claims of their ef-
fectiveness in cognitive symptoms of schizophrenia, Down syn-
drome or mood disorders (Guerrini and Ciciani, 2012; Soh and
Lynch, 2015). Development of positive allosteric modulators of
α5GABAARs has been recognized more recently as a potentially
fruitful approach in treatment of aging-related dementia (Koh
et al., 2013) and cognitive impairment in schizophrenia (Gill et al.,
2011) and autism (Mendez et al., 2013). Moreover, the results
obtained in mice with the central nucleus of the amygdala–speciﬁc
deletion of α5-GABAARs (Botta et al., 2015) as well as in mice
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that positive allosteric modulation of α5-GABAARs could be ex-
pected to interfere with maladaptive fear generalization and/or
induce anxiolytic activity, which is an additional impetus for de-
velopment of the appropriate selective ligands.
Although discovery of ligands selective for distinct GABAA re-
ceptor subtypes has become a research priority (Skolnick, 2012),
many encouraging preclinical results failed to translate to the
clinical setting (e.g. Atack et al., 2011). Suboptimal selectivity or
kinetics, lack of the needed magnitude of receptor modulation and
poor tolerability or toxicity are among possible explanations for
such failure (Atack, 2010; 2011). We have recently published an
updated model of the benzodiazepine binding site pharmacophore
of α5GABAARs (Clayton et al., 2015). The present study aimed to
obtain an α5GABAAR positive modulator with improved selectiv-
ity, and suitable to elicit a wide range of in vivo modulatory actions
on the α5GABAA receptor population within attainable doses. In
this vein, we have synthesized and pharmacokinetically and
pharmacologically characterized MP-III-022, an amide ligand
prepared from the ester precursor SH-053-2′F-R-CH3, which has
been characterized and widely studied as one of the most selective
positive modulators at α5GABAARs (Gill et al., 2011; Fischer et al.,
2010; Savić et al., 2010; Drexler et al., 2013; Soto et al., 2013;
Gallos et al., 2015).2. Materials and methods
2.1. Chemistry
(R)8-Ethynyl-6-(2-ﬂuorophenyl)-N,4-dimethyl-4H-benzo[f]
imidazo[1,5-a][1,4]diazepine-3-carboxamide (MP-III-022) (1) was
synthesized as follows.
Ester 2 (1.0 g, 2.58 mmol) (Cook et al., 2009) was added to a
sealed vessel ﬁtted with a septum at 0 °C and treated with methyl
amine (15 ml; 33% wt solution in ethanol). The vessel was sealed
with a cap and stirred at 60 °C for 18 h. The solution was then
cooled to rt and the methyl amine and ethanol were removed
under reduced pressure. The residue was puriﬁed by a wash col-
umn (silica column, 4:1 EtOAc: hexanes) to afford amide 1 as a
white powder (731 mg, 1.96 mmol, 76%). Characterization of
compound 1: 1H NMR (300 MHz, CDCl3) δ 7.88 (s, 1 H), 7.67 (dd,
J¼16.3, 7.8 Hz, 2 H), 7.55 (d, J¼8.3 Hz, 1 H), 7.50 – 7.41 (m, 2 H),
7.29 – 7.18 (m, 2 H), 7.04 (t, J¼9.3 Hz, 1 H), 6.93 (q, J¼7.4 Hz, 1 H),
3.16 (s, 1 H), 2.97 (d, J¼5.0 Hz, 3 H), 1.29 (d, J¼6.4 Hz, 3 H). 13C
NMR (300 MHz, CDCl3) δ 162.24, 161.81, 158.48, 138.25, 137.12,
135.73, 134.41, 133.57, 132.53, 131.57, 129.03, 125.15, 124.92, 124.58,
122.50, 116.33, 166.05, 81.25, 79.99, 49.42, 25.73, 25.27. HRMS
(LCMS-IT-TOF) Calc. for C22H18FN4O (M þ H)þ373.1459, found:
373.1462. Detailed spectra are provided in the Supporting In-
formation (Fig. S1 – S2).
2.2. Competition binding assays
2.2.1. Materials
3H-Flunitrazepam (speciﬁc activity 83 Ci/mmol) was purchased
from Perkin Elmer NEN (New England Nuclear)(Waltham, Massa-
chusetts, USA). Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phe-
nyl-2H-1,4, benzodiazepine-2-one) from Nycomed (Opﬁkon,
Switzerland). Standard chemicals came from Sigma-Aldrich (St.
Louis, Missouri, USA).
2.2.2. Culturing of human embryonic kidney 293 cells
Human embryonic kidney (HEK) 293 cells (American Type
Culture Collection ATCCs CRL-1574™) were maintained in Dul-
becco's modiﬁed Eagle medium (DMEM, high glucose,GlutaMAX™ supplement, Gibco 61965-059, ThermoFisher, Wal-
tham, Massachusetts, USA) supplemented with 10% fetal calf ser-
um (Sigma-Aldrich F7524, St. Louis, Missouri, USA), 100 U/ml Pe-
nicillin-Streptomycin (Gibco 15140-122, ThermoFisher, Waltham,
Massachusetts, USA) and MEM (Non-Essential Amino Acids Gibco
11140-035, ThermoFisher, Waltham, Massachusetts, USA) on 10 cm
Cell culture dishes (Cellþ , Sarstedt, Nürnbrecht, Germany) at 37 °C
and 5% CO2.
HEK293 cells were transfected with cDNAs encoding rat
GABAA-receptor subunits subcloned into pCI expression vectors.
The ratio of plasmids used for transfection with the calcium
phosphate precipitation method (Chen and Okayama, 1987) were
3 mg α(1,2,3 or 5): 3 mg β3 and 15 mg γ2 per 10 cm dish. Medium
was changed 4–6 h after transfection.
Cells were harvested 72 days after transfection by scraping into
phosphate buffered saline. After centrifugation (10 min, 12000g,
4 °C) cells were resuspended in TC50 (50 mM Tris-Citrate pH¼7.1),
homogenized with an Ultra-Turraxs (IKA, Staufen, Germany) and
centrifuged (20 min, 50 000g). Membranes were washed three
times in TC50 as described above and frozen at 20 °C until use.
2.2.3. Radioligand binding assay
Frozen membranes were thawed, resuspended in TC50 and
incubated for 90 min at 4 °C in a total of 500 ml of a solution
containing 50 mM Tris/citrate buffer, pH¼7.1, 150 mM NaCl and
2 nM [3H]-Flunitrazepam in the absence of presence of either 5 mM
diazepam (to determine unspeciﬁc binding) or various con-
centrations of receptor ligands (dissolved in DMSO, ﬁnal DMSO-
concentration 0.5%). Membranes were ﬁltered through Whatman
GF/B ﬁlters and the ﬁlters were rinsed twice with 4 ml of ice-cold
50 mM Tris/citrate buffer. Filters were transferred to scintillation
vials and subjected to scintillation counting after the addition of
3 ml Rotiszint Eco plus liquid scintillation cocktail. Nonspeciﬁc
binding determined in the presence of 5 mM Diazepam was sub-
tracted from total [3H]-Flunitrazepam binding to result in speciﬁc
binding.
In order to determine the equilibrium binding constant KD of
3H-Flunitrazepam for the various receptor-subtypes, membranes
were incubated with various concentrations of 3H-Flunitrazepam
in the absence or presence of 5 mM Diazepam.
2.2.4. Data calculation
Saturation binding experiments were analyzed using the
equation Y¼Bmax*X/(KDþX).
Nonlinear regression analysis of the displacement curves used
the equation: log(inhibitor) vs. response - variable slope with
Top¼100% and Bottom¼0% Y¼100/(1þ10^((logIC50-x)*Hill-
slope)). Both analyses were performed using GraphPad Prism
version 5.0a for Mac OS X, GraphPad Software, La Jolla California
USA, www.graphpad.com.
Drug concentrations resulting in half maximal inhibition of
speciﬁc 3H-Flunitrazepam binding (IC50) were converted to Ki
values by using the Cheng-Prusoff relationship (Cheng and Prusoff,
1973) Ki¼ IC50/(1þ(S/KD)) with S being the concentration of the
radioligand (2 nM) and the KD values listed in Table S1.
2.3. Electrophysiological experiments
cDNAs of rat GABAA receptor subunits were used for generating
the respective mRNAs that were then injected into Xenopus laevis
oocytes (Nasco, WI) as described previously (Ramerstorfer et al.,
2010) . For electrophysiological recordings, oocytes were placed on
a nylon-grid in a bath of Xenopus Ringer solution (XR, containing
90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1 mM MgCl2, 1 mM KCl
and 1 mM CaCl2). The oocytes were constantly washed by a ﬂow
of 6 ml/min XR which could be switched to XR containing GABA or
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DMSO-solutions resulting in a ﬁnal concentration of 0.1% DMSO
perfusing the oocytes. For current measurements the oocytes were
impaled with two microelectrodes (2–3 mΩ) which were ﬁlled
with 2 mM KCl. To test for modulation of GABA-induced currents
by MP-III-022, a concentration of GABA was used that was titrated
to trigger 3–5% of the respective maximum GABA-elicited current
of the individual oocyte (EC3-5). At this low GABA concentration,
within-day and between-day currents are reproducible and effects
of drugs (% of modulation) are much higher than that at higher
GABA concentrations. GABA at EC3-5 was then coapplied with
varying concentrations of MP-III-022 until a peak response was
observed. Between two applications, oocytes were washed in XR
for up to 15 min to ensure full recovery from desensitization. All
recordings were performed at room temperature at a holding
potential of 60 mV using Dagan TEV-200 two-electrode voltage
clamp ampliﬁers (Warner Instruments, Hamden, CT). Data were
digitized, recorded and measured using Digidata 1322 A and 1550
data acquisition systems (Axon Instruments, Union City, CA). Re-
sults of concentration response experiments were graphed using
GraphPad Prism 4.00 (GraphPad Software, San Diego, CA).
2.4. Studies in rats
Male outbred Wistar rats were supplied by Military Farm,
Belgrade, Serbia. Rats were housed in groups of ﬁve and were
maintained under standard laboratory conditions (2172 °C, re-
lative humidity 40–45%) with free access to pellet food and tap
water. They were kept on 12:12 h light/dark cycle with lights on at
07.00 h. All handling and testing took place during the light phase
of the diurnal cycle.
Behavioral experiments were carried out on nine weeks old
Wistar male rats weighing 200–250 g. The animals received one or
two intraperitoneal (i.p.) injections, one of which was the solvent
if not otherwise stated. The behavior was recorded by a ceiling–
mounted camera and analyzed by ANY–maze Video Tracking
System software (Stoelting Co., USA). Throughout the study, ex-
perimentally naïve animals were used. Experiments were ap-
proved by the Ethical Commission on Animal Experimentation of
the Faculty of Pharmacy in Belgrade and were carried out in ac-
cordance with the EEC Directive 86/609.
The ligands MP-III-022, SH-053-2′F-R-CH3 and XLi-093 were
synthesized at the Department of Chemistry and Biochemistry,
University of Wisconsin–Milwaukee, USA. XLi-093 is an α5GABAA
receptor selective antagonist (Savić et al., 2009). D-Amphetamine-
sulfate was purchased from Sigma–Aldrich, and ﬂumazenil from
Feicheng BoYuan Fine Chemicals Co., Ltd, China. The ligands MP-
III-022, SH-053-2′F-R-CH3, XLi-093 and ﬂumazenil were sus-
pended/dissolved with the aid of sonication in the solvent (85%
distilled water, 14% propylene glycol, and 1% Tween 80), while D-
amphetamine was dissolved in saline. All compounds were ad-
ministered i.p. in a volume of 2 ml/kg, 20 min before the beha-
vioral testing, with the exception of the experiment with D-am-
phetamine, in which the animal's behavior was recorded im-
mediately after the respective treatments.
For determination of free fractions in plasma and brain tissue,
stock solutions of MP-III-022 and SH-053-2′F-R-CH3 were pre-
pared in dimethyl sulfoxide (DMSO).
2.4.1. Pharmacokinetic study
Rats were divided in two cohorts of six groups which corre-
sponded to predetermined time intervals (5, 10, 20, 40, 60 and
180 min), each containing three animals. MP-III-022 and SH-053-
2′F-R-CH3, dosed at 2.5 mg/kg and 10 mg/kg, respectively, were
administered by i.p. injection in a volume of 2 ml/kg. Additional
experiments were performed in order to determine brain andplasma concentration 20 min after i.p. injection, as well as to
calculate free brain and plasma levels of MP-III-022 dosed at 1, 2.5,
10, 15 and 20 mg/kg, and SH-053-2′F-R-CH3 dosed at 10, 20, 30,
150 and 200 mg/kg. The blood samples were collected in hepar-
inized syringes via cardiac puncture of rats anesthetized with
ketamine solution (10% Ketamidor, Richter Pharma Ag, Wels,
Austria, dosed i.p. at 100 mg/kg), and centrifuged at 800 rcf for
10 min to obtain plasma. Thereafter, rats were decapitated and
brains were weighed, homogenized in 5 ml of methanol and
centrifuged at 3340 rcf for 20 min. To determine the concentration
of MP-III-022 and SH-053-2′F-R-CH3 in plasma and supernatants
of brain tissue homogenates, MP-III-022 and SH-053-2′F-R-CH3
were extracted from these samples by solid phase extraction,
using Oasis HLB cartridges (Waters Corporation, Milford, Massa-
chusetts). The procedure of sample preparation and determination
of MP-III-022 and SH-053-2′F-R-CH3 by ultraperformance liquid
chromatography–tandem mass spectrometry (UPLC–MS/MS) with
Thermo Scientiﬁc Accela 600 UPLC system connected to a Thermo
Scientiﬁc TSQ Quantum Access MAX triple quadrupole mass
spectrometer (Thermo Fisher Scientiﬁc, San Jose, California),
equipped with electrospray ionization (ESI) source, has been al-
ready described in detail (Obradović et al., 2014).
2.4.2. In vitro hydrolytic stability study in rat plasma
MP-III-022 and SH-053-2′F-R-CH3 were tested for their hy-
drolytic stability, utilizing blank rat plasma spiked with the re-
spective ligand (0.2 μg/ml) and internal standard (SH-I-048A;
synthesized at the Department of Chemistry and Biochemistry,
University of Wisconsin–Milwaukee, USA), and incubated in vitro
at 37 °C. Aliquots (10 ml) of this solution were then collected at
various time intervals, diluted with acetonitrile (90 ml) to pre-
cipitate any protein and analyzed using UPLC–MS/MS as above.
2.4.3. Plasma protein and brain tissue binding studies
The rapid equilibrium dialysis assay used to determine free
fraction of MP-III-022 and SH-053-2′F-R-CH3 in rat plasma and
brain tissue was the same as in Obradović et al. (2014).
2.4.4. Grip strength
Muscle strength was assessed by the grip strength meter (Ugo
Basile, Milan, Italy, model 47105). When pulled by the tail, the rat
grasps the trapeze connected to a force transducer, and the ap-
paratus measures the peak force of experimenter's pull (in grams)
necessary to overcome the strength of the animal's forelimbs grip.
Six groups received one of the following treatments 20 min before
testing: solvent, MP-III-022 (1, 2.5, 10, 15 and 20 mg/kg). Each
animal was given three consecutive trials, and the median value of
three readings, normalized against body weight, was used for
further statistics.
2.4.5. Rotarod test
Motor performance was assessed using an automated rotarod
(Ugo Basile, Italy). Before testing, rats were trained for three days
until they could remain for 180 s on the rod revolving at 15 rpm.
On the fourth day, selection was made and rats fulﬁlling the given
criteria were included in the experiment. Seven groups received
one of the following treatments 20 min before testing: solvent,
MP-III-022 (10, 15 and 20 mg/kg), SH-053-2′F-R-CH3 (200 mg/kg)
and 15 mg/kg MP-III-022 in combination with XLi-093 (20 mg/kg)
or ﬂumazenil (15 mg/kg). Latency to fall from the rotarod was
recorded automatically.
2.4.6. Intravenous pentylenetetrazole infusion test
A butterﬂy cannula (needle size 25 G, ¾ in.) attached to a 20 ml
syringe preﬁlled with pentylenetetrazole (PTZ) solution was used.
The syringe was held in adjustable motor driven infusion pump
Table 1
Binding afﬁnities of MP-III-022 (Ki) for the different receptor subtypes.
α1β3γ2 S α2β3γ2 S α3β3γ2 S α5β3γ2 S
8507110 nM 360756 nM 6607170 nM 55717 nM
The concentrations resulting in half maximal inhibition of radioligand binding were
converted into Ki values by using the Cheng-Prusoff relationship and the respective
KD values given in Table S1. Ki values are presented as mean values 7S.E.M. from
3 independent experiments performed in duplicates.
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rat's tail vein was dilated with warm water. Single rat was then
placed in the restrainer. A butterﬂy needle was inserted into the
lateral tail vein and PTZ was infused at a constant rate of 0.5 ml/
min. The animal was observed throughout the infusion by two
trained and blind observers. The threshold doses of PTZ (mg/kg)
required to elicit clonic and tonic seizures were calculated using
the following formula: volume of PTZ (ml) x concentration of PTZ
(mg/ml)/body weight (kg).
2.4.7. Spontaneous and amphetamine induced locomotor activity
Activity of single rats in a clear Plexiglas chamber
(402535 cm3) under dim red light (20 lx) was recorded for a
total of 45 min, without any habituation period but with 20 min
acclimatization time. One of two doses of MP-III-022 (10 and
15 mg/kg) or solvent were applied 20 min before testing. The same
apparatus was used for assessing the amphetamine-induced lo-
comotor activity, with an adapted protocol. Here, rats received the
appropriate treatment (solvent, 1, 2.5 or 10 mg/kg MP-III-022) and
were immediately placed in the tracking chamber. Behavior was
recorded for 20 min and then rats were injected with saline or
0.5 mg/kg amphetamine and locomotor activity was recorded for
an additional 60 min
2.4.8. Behavior in the elevated plus maze
The apparatus was constructed of black Plexiglas and consisted
of a maze elevated to a height of 50 cm with two open
(5010 cm2) and two enclosed arms (501040 cm3), con-
nected by a junction area (central platform) measured 1010 cm2.
A ledge 0.3 cm high surrounding the open arms was added. The
illumination in the experimental room consisted of one red neon
tube ﬁxed on the ceiling, giving light intensity of 10 lx on the
surface of the closed arms. At the beginning of the experiment,
single rats were placed in the center of the maze, facing one of the
enclosed arms, and their behavior was recorded for 5 min. An
entry into an open or closed arm was scored when 90% of the
animal crossed the virtual line separating the central square of the
maze from the arm, whereas an exit occurred when more than
90% of the animal left the respective arm. After each trial, the maze
was cleaned with dry and wet towels. The rats received the ap-
propriate treatment (solvent, 1, 2.5 or 10 mg/kg MP-III-022) and
20 min later were placed in the maze.
2.5. Statistics
All numerical data presented in ﬁgures are given as the
mean7S.E.M. Pharmacokinetic parameters were calculated using
PK Functions for Microsoft Excel software (by Joel Usansky, Atul
Desai, and Diane Tang-Liuwere). For the binding study, as well as
in the PTZ, grip strength, rotarod test and the elevated plus maze,
one-way ANOVA were applied. Post hoc comparisons, where ap-
plicable, were performed using SNK test, with exception of the
binding study, where Tukey test was applied. Statistical analysisScheme 1. Synthesiswas performed using SigmaPlot 11 (Systat Software Inc., Rich-
mond, USA) software. Differences were considered signiﬁcant
when Po0.05.3. Results
3.1. Chemistry
As depicted in Scheme 1, (R)8-Ethynyl-6-(2-ﬂuorophenyl)-
N,4-dimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carbox-
amide (1) was synthesized in a 76% yield by stirring ethyl ester (2)
with methyl amine in a sealed vessel.
3.2. Binding studies
Membranes from HEK-293 cells transiently expressing different
GABAA receptor subunit combinations were characterized using
3H-Flunitrazepam binding. In order to determine radioligand af-
ﬁnities to the four tested receptor subtypes (which are needed to
convert the IC50 values of a test compound into Ki values), sa-
turation binding experiments were performed. Cells were in-
cubated with various concentrations of 3H-ﬂunitrazepam and
binding data were subjected to Scatchard analysis, as described in
the methods section. The equilibrium dissociation constants of the
ligand-receptor complex obtained in saturation binding experi-
ments for four GABAA receptor subtypes are presented in Table S1.
In other experiments the potency of MP-III-022 to inhibit 2 nM
3H-ﬂunitrazepam binding to membranes from HEK-293 cells ex-
pressing four different receptor subtypes was studied. Membranes
from HEK cells transfected with the four subunit combinations
were incubated with 2 nM 3H-ﬂunitrazepam in the absence or
presence of either 5 mM diazepam (to determine nonspeciﬁc
binding) or increasing concentrations of MP-III-022. IC50 values
(i.e. drug concentrations resulting in half maximal inhibition of
speciﬁc 3H-ﬂunitrazepam binding) were converted to Ki values by
using the Cheng-Prusoff relationship (for details see methods-
section).
The determined Ki values (Table 1) of α5GABAARs differ sta-
tistically signiﬁcantly from α1- (P¼0.0011) and from α3-contain-
ing receptors (P¼0.0041) (one-way ANOVA analysis followed by
Tukey's multiple comparison test).of MP-III-022 (1).
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ceptor and enzyme assays (B. Roth et al., NIMH Psychoactive Drug
Screening Program, UNC, available at http://pdsp.med.unc.edu).
The only exception was the κ opioid receptor (KOR), at which the
secondary binding study gave the Ki value of 381 nM.3.3. Pharmacokinetic, plasma stability and free fraction studies
The concentration–time proﬁles of MP-III-022 and SH-053-2′F-
R-CH3 in rat plasma and brain after intraperitoneal administration
of the 2.5 mg/kg and 10 mg/kg dose, respectively, with the calcu-
lated pharmacokinetic parameters, are given in Fig. 1.
The doses are chosen to elicit a moderate degree of selectiveFig. 1. Plasma and brain concentration–time proﬁles of MP-III-022 (A) and SH-053-2′F-R
respectively (n¼3 per time point). Cmax¼maximum concentration in brain or plasma; T
from brain or plasma; AUC0–3¼area under the brain or plasma concentration–time curv
Fig. 2. The approximated electrophysiological responses elicited by the estimated free br
Table 3), presented on the concentration-response curves of MP-III-022 (A) and SH-0
measured at GABA EC3 (eliciting 3% of the maximal GABA current in the respective subty
concentrations from mg/kg (Tables 3 and 4) into mg/ml. The shaded range delineates the
used; the vertical lines mark the approximated free brain concentration of the given dopotentiation at α5GABAARs (see vertical markers in Fig. 2 and
explanation below). AUC (area under the curve from time 0–
180 min post-dosing) values for plasma and brain were 2-fold and
1.75-fold, respectively, greater for MP-III-022 than for SH-053-2′F-
R-CH3, despite the fact that MP-III-022 was administered at a
4-fold lower dose. In line with in vivo data of superior systemic
exposure, as assessed by AUC, the amide compound MP-III-022
displayed an excellent in vitro metabolic stability during incuba-
tion in rat plasma; this is in clear contrast with the values obtained
with the less stable ester compound SH-053-2′F-R-CH3 (Table 2).
The concentrations of MP-III-022 in rat plasma (nmol/l) and
brain tissue (nmol/kg), both total and free (estimated), measured
20 min after i.p. injection of MP-III-022 dosed at 1, 2.5, 10, 15 and-CH3 (B) after intraperitoneal administration of the 2.5 mg/kg and 10 mg/kg dose,
max¼time of maximum concentration in brain or plasma; t1/2¼elimination half-life
e from 0 to 3 h.
ain concentrations of MP-III-022 (given in Table 2) and SH-053-2′F-R-CH3 (given in
53-2′F-R-CH3 (B) at rat recombinant α1-, α2-, α3,- and α5β3γ2 GABAA receptors
pe). Brain tissue density of 1.04 g/ml (Weaver et al., 2001) was used to convert brain
interpolated lower and upper limit of potentiation at α5GABAARs in the dose range
se of each of two ligands.
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were calculated by multiplying the obtained total plasma and
brain concentrations with the appropriate free fractions (13.51%
for plasma and 6.61% for brain tissue) determined by rapid equi-
librium dialysis. The analogous results for SH-053-2′F-R-CH3 over
the same 20-fold dose schedule, but in the range from 10 mg/kg to
200 mg/kg, are presented in Table 4. Free fractions for this ester
compound were 68.55% for plasma and 3.87% for brain.
3.4. Electrophysiological effects
Dose response curves for MP-III-022 from two-electrode vol-
tage clamp experiments are shown in Fig. 2A, while the exact data
are available in the Supplementary table S2. At the α5β3γ2 GABAA
receptors, MP-III-022 elicited a signiﬁcant allosteric modulatory
efﬁcacy at concentrations starting at 10 nM, and the potentiation
values obtained at concentrations approaching 100 nM can be
described as strong efﬁcacy (above 300%). On the other hand, its
activity tended to be weakly modulatory at α2- and α3-containing
receptors only at concentrations of about 100 nM and above. MP-
III-022 lacked modulatory actions at α1-containing GABAA re-
ceptors in the whole range of in vivo free brain concentrations
which were obtained (Table S3). For comparison, a concentration
of 100 nM of SH-053-2′F-R-CH3 resulted in 11172%, 12479%,
12578%, and 18377% of control current in α1β3γ2, α2β3γ2,
α3β3γ2, and α5β3γ2 GABAA receptors, respectively (Savić et al.,
2010). Analogous to the data with MP-III-022, in Fig. 2B dose re-
sponse curves for SH-053-2′F-R-CH3 (Savić et al., 2010) are pre-
sented with approximated actions of in vivo obtainable free brain
concentrations. The exact values of potentiation read from the
curves in Fig. 2 (Table S3), suggest that efﬁcacy selectivity of MP-
III-022 is obtainable in the range from mild (below 140%) viaTable 2
Estimated in vitro metabolic stability (total plasma concentration of MP-III-022 or
SH-053-2′F-R-CH3 in 30, 60, 120 and 240 min). Mean7S.E.M., n¼3.
MP-III-022 lM % SH-053-2′F-R-
CH3
lM %
0 min 0.5556 100 0 min 0.5556 100
30 min 0.540270.0146 97.23 30 min 0.425870.0042 76.64
60 min 0.540370.0193 97.25 60 min 0.348770.0040 62.77
120 min 0.547270.0007 98.50 120 min 0.212670.0036 38.27
240 min 0.537470.0063 96.74 240 min 0.029170.0023 5.24
Table 3
Total and estimated free concentration of MP-III-022 (1, 2.5, 10, 15 and 20 mg/kg) in plas
Dose (mg/kg) 1 2.5
Plasma (nmol/l) Total 62.4374.97 120.01731.74
Free 8.4770.67 16.2974.31
Brain (nmol/kg) Total 96.47712,04 156.46750.33
Free 6.3870.80 10.3473.33
Table 4
Total and estimated free concentration of SH-053-2′F-R-CH3 (10, 20, 30, 150 and 200 mg
M., n¼2–4.
Dose (mg/kg) 10 20
Plasma (nmol/l) Total 406.43776.45 420.63770.01
Free 278.60752.39 288.32747.99
Brain (nmol/kg) Total 752.007132.84 1003.57787.55
Free 29.1075.14 38.8573.39moderate (about 160%) to strong (above 300%) potentiation at
α5GABAARs. Importantly, MP-III-022 reached strong potentiation
at α5GABAARs already at 100 nM effective concentration, at which
the effects on non-α5GABAARs were still at and below 150% (see
Fig. 2A and Table S3). In contrast, the concentration of the parent
compound needed to elicit 300% potentiation at α5GABAARs was
4300 nM, requiring exceptionally high doses of SH-053-2′F-R-
CH3, and concurrently generating in non-α5 receptors the inter-
polated potentiation in the range of 150–200%.
3.5. Grip strength, rotarod test and intravenous PTZ infusion test
MP-III-022 induced a dose-dependent decrease of muscle ten-
sion as measured by grip strength (Table 5). The ﬁrst muscle re-
laxant effect of MP-III-022 was observed at the 10 mg/kg dose.
The rats treated with 10 mg/kg MP-III-022 displayed normal
motor coordination and balance as assessed in the rotarod test, far
different from the animals treated with the 15 mg/kg, and espe-
cially 20 mg/kg dose (Table 5). The ataxic effect of 15 mg/kg MP-
III-022 was preventable by ﬂumazenil, but not XLi-093. Namely,
one-way ANOVA (F(2,18)¼5.05, P¼0.018) and Student–Newman–
Keuls (SNK) post hoc revealed signiﬁcant differences in perfor-
mance between the rats treated with 15 mg/kg MP-III-022 alone
or in combination with 20 mg/kg of XLi-093, and the combination
of 15 mg/kg MP-III-022 and 15 mg/kg ﬂumazenil (P¼0.021 and
P¼0.019, respectively, Table 5). When testing SH-053-2′F-R-CH3
on the rotarod, the ﬁrst, mild and insigniﬁcant deterioration
(154726 s vs. 180 s with control animals; n¼4) was noticed at
200 mg/kg.
One-way ANOVA applied to the PTZ test (Table 5) did not show
a statistically signiﬁcant effect of treatment with either of two
tested doses of MP-III-022 selective for α5GABAARs (F(2,30)¼1.50,
P¼0.239).
3.6. Spontaneous and amphetamine induced locomotor activity
One-way ANOVA for total distance traveled revealed a sig-
niﬁcant effect of treatment (F(2,25)¼3.64, P¼0.041) and analysis
of the SNK test showed differences between control and 15 mg/kg
MP-III-022 (P¼0.029, Fig. 3A). Similarly, when the two-way re-
peated measures ANOVA was applied on distance traveled in the
5-min bins, a signiﬁcant effect of treatment and time was revealed
(F(2,25)¼3.64, P¼0.041, F(8,200)¼32.90, Po0.001, respectively),
without a signiﬁcant interaction of factors (F(16,200)¼1.63,ma and brain 20 min after intraperitoneal treatment in rats. Mean7S.E.M., n¼3–6.
10 15 20
645.077166.29 3709.2472012.04 5378.0171936.91
87.57722.57 503.517273.13 730.047262.93
1030.527278.03 4804.4472821.77 8465.457886.18
68.12718.38 317.577186.52 559.57758.58
/kg) in plasma and brain 20 min after intraperitoneal treatment in rats. Mean7S.E.
30 150 200
555.51768.18 1604.967271.88 2737.877286.86
380.78746.73 1100.147186.36 1876.717196.63
1663.847378.29 3816.797965.21 8374.2572322.03
64.40714.64 147.74737.36 324.16789.88
Table 5
Effect of different intraperitoneal doses of MP-III-022 in the grip strength, rotarod,
and pentylenetetrazole (PTZ) test; mean7S.E.M.
grip strength
the peak force of experimenter's pull necessary to overcome the strength of
the animal's grip
Treatment Mean7S.E.M. (kg/kg) n
SOL 2.8770.17 10
1 mg/kg MP-III022 2.5770.08 10
2.5 mg/kg MP-III022 2.4170.28 8
10 mg/kg MP-III022 1.9470.22b,d 8
15 mg/kg MP-III022 1.8670.16a 5
20 mg/kg MP-III022 1.7870.16c,d 11
rotarod test
the time remaining on the rod revolving at 15 rpm
Treatment Mean7S.E.M. (s) n
10 mg/kg MP-III022 180 3
15 mg/kg MP-III022 69.09725.58 9
15 mg/kg MP-III022/20 mg/kg
XLi093
74.61734.03 6
15 mg/kg MP-III022/15 mg/kg
FLU
175.1774.83a,d 6
20 mg/kg MP-III022 6.6774.81 3
PTZ test
the threshold doses of PTZ required to elicit seizures
Treatment Mean7S.E.M. (mg/kg PTZ) n
SOL 53.3871.84 11
1 mg/kg MP-III022 60.9976.11 11
10 mg/kg MP-III022 50.9973.72 11
Grip strength: a Po0.05, b Po0.01, c Po0.001 compared to SOL, d Po0.05 com-
pared to combination of 1 mg/kg MP-III-022. Rotarod: a Po0.05 compared to
15 mg/kg MP-III-022, d Po0.05 compared to combination of 15 mg/kg MP-III-022
and 20 mg/kg XLi-093; SOL¼solvent, FLU¼ﬂumazenil
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between control and 15 mg/kg MP-III-022 (P¼0.032).
One-way ANOVA applied on data with three selective doses of
MP-III-022 (1, 2.5 and 10 mg/kg) from the ﬁrst part of the am-
phetamine-induced locomotor activity test did not show any effectFig. 3. The effects of 10 and 15 mg/kg MP-III-022 intraperitoneally on the total distan
*Po0.05 compared to control (SOL/SOL) group. All data are presented as the meanþ/7
10¼10 mg/kg MP-III-022, MP-III-022 15¼15 mg/kg MP-III-022.of treatment (F(3,28)¼0.08, P¼0.970, Fig. 4A). The same lack of
effect was observed with two-way repeated measures ANOVA on
results of 5-min intervals: Treatment: F(3,28)¼0.08, P¼0.970;
Time: F(3,84)¼78.36, Po0.001: Interaction: F(9,84)¼0.49,
P¼0.879.
Analysis of data from 60-min recordings after administration of
amphetamine with one-way ANOVA revealed a signiﬁcant effect
on total distance traveled (F(3,35)¼4.16, P¼0.007); post hoc SNK
results were given in Fig. 4B. When two-way ANOVA with re-
peated measures was applied on distance traveled in 5-min bins,
the same signiﬁcant effect was observed (Treatment: F(4,35)¼
4.16, P¼0.007, Time: F(11,385)¼5.47, Po0.001, Interaction: F
(44,385)¼2.02, Po0.001). The SNK test conﬁrmed differences
between control and all amphetamine-treated groups.
3.7. Elevated plus maze
In the elevated plus maze, treatment with MP-III-022 in the
dose range 1 mg/kg to 10 mg/kg did not affect total distance tra-
veled (F(3,28)¼1.593, P¼0.213; Fig. 5A), closed and total arm
entries (F(3,28)¼2.822, P¼0.057 and F(3,28)¼1.749, P¼0.180,
respectively; Fig. 5B), percent of open arm entries (F(3,28)¼1.455,
P¼0.248; Fig. 5C) or percent of open arm time (F(3,28)¼2.106,
P¼0.122; Fig. 5D).4. Discussion
The Ki values demonstrate that MP-III-022 possesses a 15, 6 and
12-fold selectivity in binding to α5GABAARs when compared to
binding to α1, α2 and α3-containing GABAA receptors, respec-
tively. For comparison, the Ki values for the parent ligand SH-053-
2′F-R-CH3 at α1β3γ2, α2β3γ2, α3β3γ2, and α5β3γ2 GABAA re-
ceptors were 759.1, 948.2, 768.8 and 95.2 nM, respectively (Savić
et al., 2010), which means that relative selectivity of the two li-
gands is of the same order of magnitude. It is noteworthy that MP-
III-022 is the least selective for those GABAA receptors, containing
the α2 subunit, for which SH-053-2′F-R-CH3 is the most selective
(6-fold vs. 10-fold ratio). However, selectivity for α5- against α1-ce traveled (A) and on distance traveled in 5-min bins (B) during 45 min in SLA.
S.E.M. Number of animals per treatment group was 8–10. SOL¼solvent, MP-III-022
Fig. 4. The effect of 1, 2.5, and 10 mg/kg MP-III-022 intraperitoneally on locomotor activity during 20 min before amphetamine treatment (A), the inﬂuence of 1, 2.5, and
10 mg/kg MP-III-022 on amphetamine induced hyperlocomotion during 60 min (B) and effect on distance traveled in 5-min bins during all testing (C) in locomotor activity
test. *Po0.05 compared to control (SAL/SAL) group. All data are presented as the mean þ or 7S.E.M. Number of animals per treatment group was 8. SOL¼solvent,
SAL¼vehicle, AMPH 0.5¼0.5 mg/kg amphetamine, MP-III-022 1¼1 mg/kg MP-III-022, MP-III-022 2.5¼2.5 mg/kg MP-III-022, MP-III-022 10¼10 mg/kg MP-III-022.
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for SH-053-2′F-R-CH3; this approximately two-fold greater se-
lectivity ratio may be relevant because α1-containing GABAA re-
ceptors are the subtype predominantly connected with adverse
effects of potentiation at GABAA receptors (Rudolph and Möhler,
2014).
The value of 381 nM for afﬁnity at KOR is of the same order of
magnitude as that of SH-053-2′F-R-CH3 (240 nM; B. Roth et al.,
NIMH Psychoactive Drug Screening Program, UNC, available at
http://pdsp.med.unc.edu). Although these are at least 100-fold
weaker afﬁnities than that of the declared KOR selective ligands
(Frankowski et al., 2012), the KOR Ki for MP-III-022 is on par with
that determined for α2GABAARs (360 nM), and KOR-mediated ef-
fects might be seen after the doses (15 mg/kg and above) con-
nected with high free brain concentrations of this ligand, at which
selectivity for α5-containing receptors was lost, as discussed
below.
It is well known that many enzymes (carboxylesterase, butyr-
ylcholinesterase, paraoxonase, acetylcholinesterase, albumin es-
terase) are involved in both, drug metabolism and bioconversion
of the ester-based prodrugs; particularly carboxylesterases havebeen found virtually throughout the body (Takai et al., 1997; Lie-
derer and Borchardt, 2006). Moreover, the ethyl function of an
ethyl ester, as present in SH-053-2′F-R-CH3, may be especially
labile and subject to beta-oxidation (Lijinsky et al., 1982; Bodor
and Buchwald, 2004). For these reasons, a series of amides were
synthesized (J. Cook, M. Poe, Guanguan Li, et al., unpublished re-
sults, provisional patent ﬁled in 2016), based on the pharmaco-
phore/receptor model (Clayton et al., 2015). The N-methyl analog
MP-III-022 ﬁts this model well, and analysis of the rodent data
demonstrated that MP-III-022, as a highly brain-bioavailable
benzodiazepine, provides an incrementally more favorable phar-
macokinetic proﬁle for in vivo investigation of the role of
α5GABAARs than SH-053-2′F-R-CH3. Especially, a comparison of
the unbound plasma fractions demonstrates that for each mole-
cule of MP-III-022 present free in plasma there were ﬁve such
molecules of SH-053-2′F-R-CH3, suggesting that the latter ligand
was much more susceptible to enzymes, as the performed in vitro
metabolic stability study proved.
The combined in vitro and pharmacokinetic results suggest
that MP-III-022 in the dose range 1–10 mg/kg can selectively and
gradually potentiate the α5GABAARs in a wide span from 138–
Fig. 5. The effect of 1, 2.5, and 10 mg/kg MP-III-022 administered i.p. on: distance traveled (A), total and closed arm entries (B), % of entries into the open arms (C), and % of
time spent in the open arms (D) in the elevated plus maze during 5 min of recording. All data are presented as the mean 7 S.E.M. Number of animals per treatment group
was 8 for SOL¼solvent, 9 for MP-III-022 1¼1 mg/kg MP-III-022, 7 for MP-III-022 2.5¼2.5 mg/kg MP-III-022 and 8 for MP-III-022 10¼10 mg/kg MP-III-022.
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ceptor activation disappears, and other, mostly α2/α3-containing
GABAA receptors, would begin to substantially contribute to the
overall pharmacological activity of MP-III-022. In contrast, the
estimated potentiation of GABA-mediated currents at α5GABAARs
obtained with SH-053-2′F-R-CH3 reached the value of 280% after a
huge, experimentally inconvenient dose of 200 mg/kg. In this vein,
SH-053-2′F-R-CH3 is not as applicable as MP-III-022 for in vivo
studies of the role of strong potentiation of α5GABAARs. When
compared with other published ligands besides SH-053-2′F-R-
CH3, MP-III-022 also demonstrated an improved selectivity for
α5βγ2 GABAA receptors, both in binding and functional assays (cf.
Soh and Lynch, 2015).
Studies assessing the behavioral activity of diazepam in knock-
in mice, which harbor single point-mutated receptors, have at-
tributed the muscle relaxant actions of benzodiazepines to the α2/
α3/α5-subtypes (Rudolph and Möhler, 2014). We have previously
demonstrated that the α5-selective antagonist XLi-093 can sig-
niﬁcantly diminish the myorelaxant actions of diazepam in rats
(Milić et al., 2012). Consistently, the ﬁrst muscle relaxant effect of
MP-III-022 was observed at a dose (10 mg/kg) postulated to elicit a
selective strong potentiation of α5-GABAA receptors.
The rotarod studies in knock-in mice have suggested that the
α1-, but not the α2- or α3-containing GABAA receptors contribute
to the ataxic action of diazepam (Rudolph and Möhler, 2014).
Moreover, the administration of L-838,417, a ligand with sig-
niﬁcant, but comparably small efﬁcacy at α2-, α3- and α5-
GABAARs, did not cause deﬁcits in rotarod performance in rats(Knabl et al., 2008) or mice (McKernan et al., 2000). Nonetheless,
the experiments using the nonselective, α1- and α5-subunit-se-
lective antagonists ﬂumazenil, βCCt and XLi-093, respectively,
have suggested that an effect of diazepam mediated by α2- or α3-,
but not α5-containing GABAA receptors may have contributed to
the impairing inﬂuence of diazepam on the rotarod performance
of rats (Milić et al., 2012). Accordingly, the present results imply
that a pronounced modulatory action of MP-III-022 at α2/
3GABAARs (the estimated respective potentiations at α2- and
α3GABAARs were 225% and 175% after the 15 mg/kg dose, and
280% and 200% after the 20 mg/kg dose; for comparison, the es-
timated potentiation at α2GABAARs after the dose of 10 mg/kg was
138% and the estimated free concentration was only 19% of Ki
value for this receptor subtype) still can induce ataxia. The dif-
ferences in dose-dependency of behavioral response in two tests
demonstrate that the rotarod-ataxic effects of MP-III-022 may
encompass, but do not solely rely on muscle relaxation. SH-053-2′
F-R-CH3 induced a mild and insigniﬁcant rotarod incapacitation at
the dose as high as 200 mg/kg, at which the estimated potentia-
tions at α2- and α3GABAARs were 171% and 155%, respectively, i.e.
were lower than those after the 15 mg/kg dose of MP-III-022.
Higher doses of SH-053-2′F-R-CH3 most probably required for
marked incapacitation (for comparison, the S-isomer of this ligand,
SH-053-2′F-S-CH3, displayed a median incapacitating dose of
219 mg/kg (Savić et al., 2008)) were not tested due to ethical
constraints and irrelevancy, as they need to be accompanied by a
distinct lack of selectivity of receptor subtype action. Keeping in
mind the efﬁcacy and kinetic properties of MP-III-022, the whole
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strated that the 15 mg/kg dose of MP-III-022 is behaviorally non-
selective. Thus, the PTZ test was performed with selective doses
only and the results were consistent with the proposed con-
tribution of the non-α5 containing receptors to the anticonvulsant
action of GABAergic drugs (Crestani et al., 2002).
The spontaneous locomotor activity test was performed with
the highest selective (10 mg/kg) and lowest non-selective (15 mg/
kg) dose of MP-III-022. The slight hyperlocomotion observed after
treatment with the 15 mg/kg dose could be ascribed to a kind of
behavioral disinhibition induced by potentiation of α2/3-contain-
ing GABAA receptors unopposed by activity at α1-containing re-
ceptors (Savić et al., 2009). As an important corollary, the as-
sumption that α5GABAARs may contribute to the sedative prop-
erties of benzodiazepine site agonists (Savić et al., 2008; 2010)
would most probably not apply to a substantial level of potentia-
tion, such as that elicited by 10 mg/kg MP-III-022. Recent studies
with allegedly selective positive as well as negative modulators of
α5GABAA receptors reported a slight, but still signiﬁcant sup-
pression of the amphetamine-induced locomotor stimulation in
the sensitized, behaviorally altered, animals (Gill et al., 2011; Re-
drobe et al., 2012); the present data demonstrate the lack of in-
ﬂuence of α5 receptor-selective doses of MP-III-022 on ampheta-
mine's effects in normal wild-type animals.
The lack of signiﬁcant effects of MP-III-022 in the elevated plus
maze is in agreement with a number of previous studies ex-
amining the relation between α5GABAARs and anxiety (Crestani
et al., 2002; Dawson et al., 2006; Savić et al., 2008; 2010). It is less
clear how these results can be linked with the recent suggestions
that generalization of fear and anxiety is mediated by α5-subunit
containing neurons in the central nucleus of the amygdala, where
reduced expression of α5-GABAARs was proved to be anxiogenic
(Botta et al., 2015), or that the anxiolytic effect of diazepam is
preserved in mice rendered sensitive to its modulatory action
solely via α5-GABAARs (Behlke et al., 2016). The latter studies were
performed in genetically modiﬁed mice, while the present study
dealt with native rats, so that both, species and genetic diversity
may have been the source of variability. Moreover, observation of
the relative time spent in open arms in the elevated plus maze
(Fig. 5D) may suggest a potential of MP-III-022 to induce, under
certain conditions, an anxiogenic-like action, at a low and high,
but not middle dose. This may be apparently at odds with the
ﬁnding, based on non-parametric statistical analysis, that an afﬁ-
nity-selective negative modulator at α5-GABAARs exerted both a
U-shaped anxiogenic (decreased open-arm activity) and stimula-
tory effect (increased closed-arm activity) in the murine elevated
plus maze (Navarro et al., 2002). As we previously discussed for
locomotor inﬂuences (Savić et al., 2008), the behavioral output in
general, and anxiety in particular, may be modulated by certain,
experimentally hardly accessible, ‘discontinuous effective win-
dows’ generated by neurons expressing α5-GABAARs.5. Conclusions
By approximation of the electrophysiological responses which
estimated free rat brain concentrations can induce, we demon-
strated that systemic administration of MP-III-022 at doses be-
tween 1 and 10 mg/kg should result in a wide range of selective
potentiation at α5GABAARs, from mild to moderate to strong, the
latter of which is not conveniently attainable after dosing with the
parent compound SH-053-2′F-R-CH3. This was not accompanied
by overt behavioral impairments which would be suggestive of
safety issues. Namely, in the rotarod, pentylenetetrazole as well as
spontaneous and amphetamine-induced locomotor activity tests,
MP-III-022 at doses up to 10 mg/kg proved to be behaviorallysilent in rats, and the only motor effect of that dose was a mild,
though signiﬁcant muscle relaxation expectedly observed in the
grip strength test. Moreover, MP-III-022 proved to be devoid of
inﬂuence on the anxiety level. Thus, it would be possible to se-
lectively assess the behavioral consequences of eliciting a wide
range of potentiation of α5GABAARs in a set of rodent behavioral
tests modeling human disorders, especially those with cognitive
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